Research Analysts’ Weekly Ratings Changes for Ascendis Pharma A/S (ASND)

Several analysts have recently updated their ratings and price targets for Ascendis Pharma A/S (NASDAQ: ASND):

• 1/27/2026 – Ascendis Pharma A/S is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $342.00 price target on the stock.
• 1/27/2026 – Ascendis Pharma A/S is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $342.00 price target on the stock.
• 1/21/2026 – Ascendis Pharma A/S had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – Ascendis Pharma A/S had its price target raised by analysts at Royal Bank Of Canada from $245.00 to $250.00. They now have an “outperform” rating on the stock.
• 1/20/2026 – Ascendis Pharma A/S had its price target raised by analysts at Wells Fargo & Company from $322.00 to $330.00. They now have an “overweight” rating on the stock.
• 1/9/2026 – Ascendis Pharma A/S had its price target raised by analysts at Wells Fargo & Company from $297.00 to $322.00. They now have an “overweight” rating on the stock.
• 1/7/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/7/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by analysts at TD Cowen. They now have a $325.00 price target on the stock.
• 12/11/2025 – Ascendis Pharma A/S had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a “buy” rating on the stock.

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.